Bristol-myers Squibb Compnay

Bristol-myers Squibb Pharma Company

Viiv Healthcare UK (no. 4) Limited

Viiv Healthcare UK (no.5) Limited

Lexicon Pharmaceuticals, Inc.

Syngene International Limited

Viiv Healthcare UK Limited

Richard A Hartz

Vijay T Ahuja

John E Macor

Alicia Regueiro-Ren

Nicholas A Meanwell

Sing-Yuen Sit

Yan Chen

Joanne J Bronson

Jie Chen

Jacob Swidorski

Ny Sin

Brian Lee Venables

Li Xu

Carolyn Diane Dzierba

Argyrios George Arvanitis

Zheng Liu

Susheel Jethanand Nara

Vivekananda M Vrudhula

Paul Joseph Gilligan

Gene Michael Dubowchik

Prasanna Sivaprakasam

Ramkumar Rajamani

Bireshwar Dasgupta

Ira B Dicker

Beata Nowicka-Sans

Guanglin Luo

Kenneth Gordon Carson

Yulian Zhang

Satheesh Kesavan Nair

Yingzhi Bi

Michael Alan Green

Giovanni Cianchetta

Manoranjan Panda

Ling Chen

Prasada Rao Jalagam

Maheswaran Sivasamban Karatholuvhu

David S Yoon

Swanee E Jacutin-Porte

Senliang Pan

S Roy Kimura

David Kimball

Soojin Kwon

Greg Zipp

Alicia Regueiro-ren

Michael Green

The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.

Tetrahydropyran-based thiodisaccharide mimics as Galectin-3 inhibitors

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.

C-3 and C-17 modified triterpenoids as HIV-1 inhibitors

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from Ccycloalkyl, Ccycloalkenyl, Cspirocycloalkyl, Cspirocycloalkenyl, Coxacycloalkyl, Cdioxacycloalkyl, Coxacycloalkenyl, Cdioxacycloalkenyl, Ccyclodialkenyl, Coxacyclodialkenyl, Coxaspirocycloalkyl and Coxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is &#x2014;Calkyl-halo. These compounds are useful for the treatment of HIV and AIDS.

Triterpenoids with HIV maturation inhibitory activity

The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3. 

GSK-3 inhibitors

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3. 

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I:  These compounds are useful for the treatment of HIV and AIDS.

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

Aryl lactam kinase inhibitors

Heterocyclic kinase inhibitors

The present disclosure is generally directed to compounds of formula (I) which can inhibit AAKI (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAKI. 

Quinoline-based kinase inhibitors

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, alkyl and alkenyl C-3 modified betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II, III and IV: a compound of Formula I     The compounds are useful for the treatment of HIV and AIDS.

C-3 alkyl and alkenyl modified betulinic acid derivatives

The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds are CRF receptor antagonists and may be useful for treating disorders associated with abnormal CRF levels or aberrant functioning of CRF receptors. 

Substituted carbamate derivatives as modulators of corticotropin-releasing factor receptor activity

The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF.

Pyrazinone modulator of corticotropin-releasing factor receptor activity

The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled receptor 88.

Modulators of G protein-coupled receptor 88

Growing community of inventors

Middletown, CT, United States of America

Richard A Hartz